Newly Listed Guardian Pharmacy Is Well Positioned In Highly Fragmented Market, Analyst Initiates With Buy Rating
Newly Listed Guardian Pharmacy Is Well Positioned In Highly Fragmented Market, Analyst Initiates With Buy Rating
Truist notes the sizable market opportunity of around $24.8 billion of U.S. institutional pharmacy revenue in 2024.Truist Securities has initiated coverage on Guardian Pharmacy Services, Inc (NYSE:GRDN), which operates long-term care pharmacies that facilitate the full lifecycle of pharmacy administration and associated consultative services for residents of long-term healthcare facilities (LTCFs).
Truist Securities已开始对长期护理药房服务公司Guardian Pharmacy Services, Inc (NYSE:GRDN) 进行覆盖，该公司经营长期护理药房，提供长期医疗保健设施（LTCFs）居民的全面药房管理和相关咨询服务。
As of June 30, 2024, the company operated 50 pharmacies that served approximately 174,000 residents in approximately 6,700 LTCFs across 36 states.
截至2024年6月30日，该公司运营着50家药房，为36个州的大约6,700个LTCFs的约174,000名居民提供服务。
Guardian Pharmacy Services priced its initial public offering of 8 million shares at $14.00 per share. The company started trading on September 26.
Guardian Pharmacy Services以每股14.00美元的价格定价其800万股的首次公开发行。该公司于9月26日开始交易。
Truist notes the sizable market opportunity of around $24.8 billion of U.S. institutional pharmacy revenue in 2024.
Truist指出，2024年美国机构药房收入约为248亿美元的巨大市场机会。
The analyst observes strong industry trends driven by the aging U.S. population and an increase in residents at assisted living facilities, along with a rise in chronic conditions and multiple diagnoses.
分析师观察到由美国人口老龄化、辅助生活设施居民增加、慢性疾病和多诊断增加等驱动的强劲行业趋势。
"Given these industry dynamics, we view Guardian as well positioned given their differentiated scale, suite of capabilities," Truist analyst writes.
"鉴于这些行业动态，我们认为Guardian在很好的定位，由于其与众不同的规模和一系列能力，" Truist分析师写道。
The analyst sees a market share of over 12%, with a leading presence in many regions and an impressive assisted living resident adoption rate of approximately 88%.
分析师认为其市场份额超过12％，在许多地区具有领先地位，并且在辅助生活居民采用率上达到约88％的印象深刻。
The analyst adds that Guardian has strategically targeted the more lucrative markets of assisted living and behavioral health facilities/group homes.
分析师补充说，Guardian已经战略地瞄准了更有利可图的辅助生活和行为健康机构/集体住所市场。
The analyst initiates with a Buy rating and a price target of $22.
该分析师首次给予买入评级，并设定22美元的目标价格。
Truist says the industry dynamics are advantageous, as the market is notably fragmented, and regulatory requirements create significant barriers to entry. Additionally, demographic trends are likely to provide a boost, particularly as the aging population increasingly relies on prescription medications.
Truist表示，行业动态有利，市场明显分散，监管要求造成了重要的准入壁垒。此外，人口结构趋势可能会提供提振，尤其是随着老龄化人口越来越依赖处方药。
Stable margins have accompanied Guardian's rapid membership growth, and the company's strong cash flow and appealing financial flexibility will enable continued investments in growth and M&A, the analyst says.
分析师表示，稳定的利润率伴随着Guardian快速增长的会员数量，公司强劲的现金流和吸引人的财务灵活性将使其能够继续投资于增长和并购。
Lastly, Truist foresees ongoing expansion efforts in new and established markets via organically and M&A activities.
最后，Truist预计通过有机扩张和并购活动在新兴和成熟市场进行持续扩张。
Price Action: GRDN stock is down 1.13% at $17.48 at last check Monday.
股价走势：GRDN股票在上周一最后查看时下跌了1.13%，报17.48美元。
Image: Akava Photo from Pixabay
图片来自Pixabay的Akava照片。
- Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug.
- Eli Lilly起诉一些供应商未经授权销售假减肥药。
